Barry Flannelly Buys Shares of Protara Therapeutics, Inc. $TARA
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barry Flannelly, insider at Protara Therapeutics, Inc. ($TARA), bought 31,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Protara Therapeutics, Inc. Stock Down 0.3%
Shares of Protara Therapeutics, Inc. ($TARA) traded around $3.81 on Wednesday, down 0.3% for the day.
Protara Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Protara Therapeutics, Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Get Protara Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TARA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.